Breast cancer
NEW --- CDK4/6 inhibitors for everyone? First-line treatment strategies in HR+ HER2- MBC
Educational Objective: Choose the most appropriate first-line systemic therapy for patients with synchronous or metachronous HR+ HER2- advanced breast cancer.
Specialty: Medical oncology, Clinical oncology, (Obstetrics & Gynaecology)
Target Audience: Specialists (CME: basic, intermediate), Residents (senior)
Latest update: March 2025
Background:
Regulatory approval status of endocrine and targeted therapies included in this topic (indications limited to hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer, status 18 March 2025)
ABC: advanced breast cancer; AI: aromatase inhibitor; ER+: oestrogen receptor-positive; ET: endocrine therapy; HER2-: human epidermal growth factor receptor 2-negative; HR+: hormone receptor-positive; LHRH: luteinizing hormone-releasing hormone; MBC: metastatic breast cancer